Literature DB >> 20504759

[Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region].

F Ducimetière1, A Lurkin, D Ranchère-Vince, A-V Decouvelaere, S Isaac, C Claret-Tournier, Y Suignard, D Salameire, D Cellier, L Alberti, P-P Bringuier, J-Y Blay, I Ray-Coquard.   

Abstract

Sarcomas comprise a heterogeneous group of mesenchymal neoplasms. They can be grouped into 3 general categories, soft tissue sarcoma, visceral and primary bone sarcoma, which have different staging and treatment approaches. Soft tissue sarcomas are typically classified on the basis of genetic alterations and light-microscopic examination of hematoxylin-eosin-stained tissue, in which recognizable morphological characteristics of normal tissues are identified. Sarcomas are further characterized by histologic grade. The 3 most important prognostic variables are grade, size, and location of the primary tumor. This review includes a discussion of both soft tissue sarcomas (unclassified sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, dermatofibrosarcoma protuberans, angiosarcoma, Kaposi sarcoma, gastrointestinal stromal tumor, rhabdomyosarcoma, ...) and primary bone sarcomas (osteosarcoma, Ewing sarcoma and chondrosarcoma). The approach to a patient with a sarcoma begins with a biopsy that obtains adequate tissue for diagnosis without interfering with subsequent optimal definitive surgery. Subsequent treatment depends on the specific type of sarcoma. Due to the absence of clear knowledge for incidence rate, we conducted in 2005 and 2006 an exhaustive analysis of all diagnosed cases in the Rhône-Alpes region. Because sarcomas are relatively uncommon yet comprise a wide variety of different entities, second opinion was systematically performed for all included cases.

Entities:  

Mesh:

Year:  2010        PMID: 20504759     DOI: 10.1684/bdc.2010.1117

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  7 in total

1.  Our experience with laparoscopic partial gastrectomy by the 'lift-and-cut method' for gastric gastrointestinal stromal tumor with maximal preservation of the remnant stomach.

Authors:  Shintaro Okumura; Seiichiro Kanaya; Hisahiro Hosogi; Takeshi Ito; Susumu Miura; Toshihiro Okada; Norihiro Shimoike; Shin Akagawa; Hironori Kawada; Akira Arimoto
Journal:  Surg Endosc       Date:  2016-12-06       Impact factor: 4.584

Review 2.  Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.

Authors:  Shreyaskumar Patel
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

3.  Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions.

Authors:  I Ray-Coquard; M C Montesco; J M Coindre; A P Dei Tos; A Lurkin; D Ranchère-Vince; A Vecchiato; A V Decouvelaere; S Mathoulin-Pélissier; S Albert; P Cousin; D Cellier; L Toffolatti; C R Rossi; J Y Blay
Journal:  Ann Oncol       Date:  2012-02-13       Impact factor: 32.976

4.  Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region.

Authors:  Pierre Etienne Heudel; Philippe Cousin; Antoine Lurkin; Claire Cropet; Françoise Ducimetiere; Olivier Collard; Guy De Laroche; Pierre Biron; Pierre Meeus; Philippe Thiesse; Christophe Bergeron; Gualter Vaz; François Mithieux; Fadila Farsi; Yohan Fayet; François-Noel Gilly; Dominic Cellier; Jean-Yves Blay; Isabelle Ray-Coquard
Journal:  Int J Clin Oncol       Date:  2013-08-10       Impact factor: 3.402

5.  Retrospective study of laparoscopic versus open gastric resection for gastric gastrointestinal stromal tumors based on the propensity score matching method.

Authors:  Chao Xu; Tao Chen; Yanfeng Hu; A I Balde; Hao Liu; Jiang Yu; Li Zhen; Guoxin Li
Journal:  Surg Endosc       Date:  2016-06-10       Impact factor: 4.584

6.  CASE REPORT Sternal Chondrosarcoma After Sternotomy for Coronary Artery Bypass Grafting.

Authors:  Vijay A Singh; Juan Abreu; Kimberly Bowman; Masood A Shariff; Joseph T McGinn
Journal:  Eplasty       Date:  2013-01-24

7.  Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.

Authors:  Carmela Dantas-Barbosa; Tom Lesluyes; François Le Loarer; Fréderic Chibon; Isabelle Treilleux; Jean-Michel Coindre; Pierre Meeus; Mehdi Brahmi; Olivia Bally; Isabelle Ray-Coquard; Marie-Pierre Sunyach; Axel Le Cesne; Olivier Mir; Sylvie Bonvalot; Maud Toulmonde; Antoine Italiano; Pierre Saintigny; Myriam Jean-Denis; Francoise Ducimetiere; Dominique Ranchere; Hiba El Sayadi; Laurent Alberti; Jean-Yves Blay
Journal:  Br J Cancer       Date:  2017-10-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.